

MEETING ABSTRACT

Open Access

Protective effect of silymarin on doxorubicininduced cardiotoxicity in rats

Nebojša Stilinović*, Aleksandar Rašković, Momir Mikov, Saša Vukmirović, Boris Milijašević

From 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the Croatian, Serbian and Slovenian Pharmacological Societies. Graz, Austria. 20-21 September 2012

Background

Silymarin, an extract of *Silybum marianum* seeds, possesses a broad spectrum of action: antifibrotic, antiinflammatory, lipid peroxidation-inhibiting and free radical-scavenging effects. It is a complex of five major compounds, and silibinin is the most biologically active component of the complex. The aim of this study was to investigate, evaluate and confirm the potential antioxidative effects of silymarin rich in silibinin.

Methods

White laboratory rats of Wistar type were used in this experiment. They were treated with saline, 1 ml/kg, orally; olive oil 1 ml/kg, orally; silymarin, 60 mg/kg, orally, every day; with doxorubicin, 1.66 mg/kg, intraperitoneally, every second day; and with the combination of silymarin and doxorubicin in the stated doses. The animals were anaesthetised with urethane and a prepared jugular vein was connected to an infusion pump with verapamil in the course of recording an electrocardiogram. Then, animals were sacrificed by cardiopunction and blood samples were taken to determine serum enzymes activity.

Results

The results show that the treatment with silymarin and doxorubicin in combination causes statistically significant increase of the verapamil dose necessary to produce first change (2.21:0.62, p < 0.01); continuous reaction (2.77:1.5, p < 0.05) and toxic effect (3.38:1.87, p < 0.05) in comparison to the groups treated with doxorubicin alone. The administration of silymarin prevented an increase of creatine kinase activity induced by doxorubicin (279:616; p < 0.01). The activity of lactate dehydrogenase was not

significantly different between groups. Silymarin also prevented the doxorubicin-induced increase in aspartate aminotransferase activity (349.5:279.5, p < 0.05).

Concusions

On the basis of the results it can be concluded that prooxidative activity of doxorubicin is significantly lower when it is administered in combination with silymarin.

Acknowledgements

This work was supported by the Provincial Secretariat for Science and Technological Development, Autonomous Province of Vojvodina, project no. 114-451-2458/2011.

Published: 17 September 2012

doi:10.1186/2050-6511-13-S1-A9

Cite this article as: Stilinović *et al.*: Protective effect of silymarin on doxorubicin-induced cardiotoxicity in rats. *BMC Pharmacology and Toxicology* 2012 **13**(Suppl 1):A9.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia



^{*} Correspondence: nebojsa.stilinovic@uns.ac.rs

Department of Pharmacology Toxicology and C